Looking Deeper Into Genetic Variants Of FSGS, With Jennifer Lai Yee, MD, PhD, MPH
The 2021 kidney diseases improving global outcomes (kdigo) classification of fsgs encompasses clinical presentation, genetic variants, and histopathology with the goal of. Patients with the genetic form of focal segmental glomerulosclerosis (gfsgs) benefitted from sparsentan treatment, similarly to those with other forms of fsgs. Sparsentan was similarly effective in treating patients with genetic focal segmental glomerulosclerosis (fsgs) as it was in treating those with other forms of fsgs, according to a. Identified all 8 known fs or focal segmental glomerulosclerosis (fsgs) variants and 16 additional novel variants which were comparably disruptive to these known pathogenic. Sparsentan demonstrated a more pronounced antiproteinuric effect in gfsgs patients compared to irbesartan, sustained throughout the study period.
Fsgs caused by mutations in nephrin, podocin, cd2ap , plcε1 and myo1e is characterized by an autosomal recessive pattern of inheritance. As a rule, onset of disease is.